A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 (NCT06539507)
A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
Who can join: Review the eligibility criteria below.
Location: Stanford University School of Medicine — Palo Alto, California
Age range: 12 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Stanford University School of Medicine — Palo Alto, California
- Therapeutics Clinical Research — San Diego, California
- Yale Center for Clinical Investigation — New Haven, Connecticut
- Northwestern Dermatology CTU — Chicago, Illinois
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana
- Westmead Hospital - Department of Dermatology — Sydney, New South Wales
- Nucleus Network — Brisbane, Queensland
- Veracity Clinical Research — Brisbane, Queensland
- Hôpital Saint-Louis — Paris,
- Universitätsklinikum Heidelberg — Heidelberg,
- Maastricht Universitair Medisch Centrum (MUMC+) — Maastricht,
- Erasmus Universitair Medisch Centrum (EMC) — Rotterdam,
📞 Contact the Study Coordinator
Phone: (919) 859-1302
Email: clinicaltrials@biocryst.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Netherton Syndrome
- Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome — San Diego, California
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome — San Diego, California
- Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome — Chicago, Illinois
- Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome — Fremont, California
Explore by condition: All Netherton Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.